Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


‘Unsavoury’ Practices: Pharma Will Need To Be More Transparent On CME Expenses In India

Faces Audits Under Revised Rules

Executive Summary

India’s revised code for marketing practices includes US Sunshine Act-like requirements converging with tax laws and puts the spotlight on continuing medical education initiatives, where pharma will need to display funding/expenditure data on their website. The Pink Sheet talks to experts on the implications and also new requirements on brand reminders and drug samples.

You may also be interested in...

India Compliance Shifts: Pharma’s Marketing Stack Has Big Opportunities For Health-Tech

Pharma may need to reorient its sales and marketing approach in India amid tighter regulatory scrutiny and growing digital adoption by physicians, opening up new opportunities for digital health startups to innovate across the commercialization value chain, indicates a leading venture capital firm.

OPPI’s Matai On Winds Of Policy Change In India, Quality Oversight

Incoming director general of the Organisation of Pharmaceutical Producers of India, Anil Matai, talks to Scrip about the evolving policy and regulatory landscape in India in areas such as R&D and quality. Stricter adherence to ethical marketing practices and transparency in interactions between pharma and physicians could be key focus areas in the coming year, he adds.

India Physician Conduct Rules Want Them Off Pharma-Sponsored Symposia

Wider-ranging new draft rules suggest that physicians in India should not engage in educational activity sponsored by pharma and urges them to declare financial earnings and benefits received from industry via an affidavit. The Pink Sheet discusses with industry experts some of the nuances and seeming loopholes in the rules, currently in self-regulatory mode but with penalties proposed for violation.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts